Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug
11/05/2023 04:36
May 11 (Reuters) - The U.S. Food and Drug Administration
approved Otsuka Pharmaceutical's 4578.T brexpiprazole to treat
agitation in patients with Alzheimer's on Thursday, making it
the first approved drug for the indication, the company said in
a statement.
The decision comes after an advisory panel in April voted
9-1 that the company had enough data to identify the population
in whom benefits from the treatment outweighs its risks.
(Reporting by Aditya Samal; Editing by Shounak Dasgupta)
((Aditya.Samal@thomsonreuters.com))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug